Intralesional steroid in the era of propranolol for infantile hemangioma-Do we need it?
Copyright © 2022 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved..
INTRODUCTION: Despite its effectivity, there are reports of poor response to propranolol in the treatment of infantile hemangioma (IH). The literature is limited to the type of IH that fails to respond to propranolol. This study was conducted to analyze which types of hemangiomas respond poorly to propranolol and the effects of intralesional triamcinolone (IL TMC) in them.
MATERIAL AND METHODS: In this prospective cohort study, IH was classified as superficial, deep, and mixed. The clinical details were recorded. Propranolol was started in the patients at a dose of 1 mg/kg/day and increased to 2-3 mg/kg/day. The response to the treatment was evaluated as excellent, good, poor, and no response. IL TMC was given in the non-responding group at a dose of 1-2 mg/kg at one-month interval for a total of six doses after stopping propranolol.
RESULTS: Ninety-six patients (median age, 7 months; M/F = 2:1) were treated. Superficial hemangioma was present in 40 (41.7%), deep in 10 (10.4%), and mixed in 46 (47.9%) patients. The response was statistically better if initiated within four months of age. It was not influenced by the sex, number, site, or size. The response was statistically better in superficial hemangioma. IL TMC was administered in the 16 patients. The response was good or excellent in 10 patients.
CONCLUSION: Propranolol will be used as a first-line drug for IH. All superficial IHs are likely to respond. There will be a possibility of non-responding mixed or deep IH. Use of IL TMC seems reasonable for IH not responding to propranolol.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
|---|---|
| Enthalten in: |
Journal of plastic, reconstructive & aesthetic surgery : JPRAS - 77(2023) vom: 15. Feb., Seite 117-122 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pandey, Anand [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9Y8NXQ24VQ |
|---|
| Anmerkungen: |
Date Completed 07.02.2023 Date Revised 16.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bjps.2022.11.038 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350781354 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350781354 | ||
| 003 | DE-627 | ||
| 005 | 20231226045756.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bjps.2022.11.038 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350781354 | ||
| 035 | |a (NLM)36566639 | ||
| 035 | |a (PII)S1748-6815(22)00671-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pandey, Anand |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intralesional steroid in the era of propranolol for infantile hemangioma-Do we need it? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.02.2023 | ||
| 500 | |a Date Revised 16.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a INTRODUCTION: Despite its effectivity, there are reports of poor response to propranolol in the treatment of infantile hemangioma (IH). The literature is limited to the type of IH that fails to respond to propranolol. This study was conducted to analyze which types of hemangiomas respond poorly to propranolol and the effects of intralesional triamcinolone (IL TMC) in them | ||
| 520 | |a MATERIAL AND METHODS: In this prospective cohort study, IH was classified as superficial, deep, and mixed. The clinical details were recorded. Propranolol was started in the patients at a dose of 1 mg/kg/day and increased to 2-3 mg/kg/day. The response to the treatment was evaluated as excellent, good, poor, and no response. IL TMC was given in the non-responding group at a dose of 1-2 mg/kg at one-month interval for a total of six doses after stopping propranolol | ||
| 520 | |a RESULTS: Ninety-six patients (median age, 7 months; M/F = 2:1) were treated. Superficial hemangioma was present in 40 (41.7%), deep in 10 (10.4%), and mixed in 46 (47.9%) patients. The response was statistically better if initiated within four months of age. It was not influenced by the sex, number, site, or size. The response was statistically better in superficial hemangioma. IL TMC was administered in the 16 patients. The response was good or excellent in 10 patients | ||
| 520 | |a CONCLUSION: Propranolol will be used as a first-line drug for IH. All superficial IHs are likely to respond. There will be a possibility of non-responding mixed or deep IH. Use of IL TMC seems reasonable for IH not responding to propranolol | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Infantile hemangioma | |
| 650 | 4 | |a Intralesional triamcinolone | |
| 650 | 4 | |a Propranolol | |
| 650 | 4 | |a Treatment failure | |
| 650 | 7 | |a Propranolol |2 NLM | |
| 650 | 7 | |a 9Y8NXQ24VQ |2 NLM | |
| 650 | 7 | |a Adrenergic beta-Antagonists |2 NLM | |
| 700 | 1 | |a Srivastava, Anurag |e verfasserin |4 aut | |
| 700 | 1 | |a Pant, Nitin |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Sudhir |e verfasserin |4 aut | |
| 700 | 1 | |a Rawat, Jiledar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of plastic, reconstructive & aesthetic surgery : JPRAS |d 2006 |g 77(2023) vom: 15. Feb., Seite 117-122 |w (DE-627)NLM160758319 |x 1878-0539 |7 nnns |
| 773 | 1 | 8 | |g volume:77 |g year:2023 |g day:15 |g month:02 |g pages:117-122 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bjps.2022.11.038 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 77 |j 2023 |b 15 |c 02 |h 117-122 | ||